Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model

Hayato Nishimura, Yasuhiko Ito, Masashi Mizuno, Akio Tanaka, Yoshiki Morita, Shoichi Maruyama, Yukio Yuzawa, Seiichi Matsuo

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Peritoneal fibrosis (PF) is an important complication of long-term peritoneal dialysis. Although mineralocorticoid and mineralocorticoid receptor (MR) have attracted increasing attention in the field of vascular injury, including the heart, kidney, and vessels, little is known about the role of mineralocorticoid in PF. This work was designed to explore the effects of MR blockade on PF. We developed a new model of PF in rats based on mechanical scraping of the peritoneum. This model is characterized by acute-phase inflammation (neutrophil and macrophage infiltration on days 0-3) and late-phase PF (α-smooth muscle actin-positive fibroblast infiltration, type III collagen accumulation, and neoangiogenesis on days 7-14). Peritoneal thickening peaked on day 14. MR was expressed in rat peritoneum and a rat fibroblast cell line. Expression of its effector kinase [serum- and glucocorticoid-induced kinase-1 (Sgk1)], transforming growth factor-β (TGF-β), plasminogen activator inhibitor-1 (PAI-1), and CD31-positive vessels increased during the course of PF. Rats were treated with spironolactone, angiotensin receptor blockade (ARB), or angiotensin-converting enzyme inhibitor (ACEI)-ARB- spironolactone starting at 6 h after peritoneal scraping. All parameters, including peritoneal thickening, number of macrophages and CD31-positive vessels, and expression of monocyte chemoattractant protein-1, TGF-β, PAI-1, and Sgk1, were significantly suppressed by spironolactone (10 mg·kg-1 ·day-1). The effects of spironolactone (10 and 20 mg·kg-1 ·day-1) were very similar to those of triple blockade. ARB, but not ACEI, significantly reduced peritoneal thickening. Furthermore, peritoneal function assessed by peritoneal equilibration test was significantly improved by spironolactone. Our results suggest that MR is a potential target to prevent inflammation-induced PF in patients on peritoneal dialysis.

Original languageEnglish
Pages (from-to)F1084-F1093
JournalAmerican Journal of Physiology - Renal Physiology
Volume294
Issue number5
DOIs
Publication statusPublished - 01-05-2008

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Physiology
  • Urology

Cite this